Article
Safety of Quadrivalent Meningococcal Conjugate Vaccine in 11- to 21-Year-Olds
Hung-Fu Tseng, Lina S. Sy, Bradley K. Ackerson, Rulin C. Hechter, Sara Y. Tartof, Mendel Haag, Jeffrey M. Slezak, Yi Luo, Christine A. Fischetti, Harp S. Takhar, Yan Miao, Marianne Cunnington, Zendi Solano and Steven J. Jacobsen
Pediatrics December 2016, e20162084; DOI: https://doi.org/10.1542/peds.2016-2084
Hung-Fu Tseng
aDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California;
Lina S. Sy
aDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California;
Bradley K. Ackerson
bPediatrics and Pediatric Infectious Diseases, Southern California Permanente Medical Group, Harbor City, California;
Rulin C. Hechter
aDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California;
Sara Y. Tartof
aDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California;
Mendel Haag
cSeqirus Netherlands B.V., Amsterdam, Netherlands;
Jeffrey M. Slezak
aDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California;
Yi Luo
aDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California;
Christine A. Fischetti
aDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California;
Harp S. Takhar
aDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California;
Yan Miao
dGlaxoSmithKline B.V., Amsterdam, Netherlands; and
Marianne Cunnington
eGlaxoSmithKline plc, London, United Kingdom
Zendi Solano
aDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California;
Steven J. Jacobsen
aDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California;